Azienda Ospedaliera Universitaria Integrata Verona

4月4日，强生公司对外宣布，其TREMFYA®（guselkumab）的3b期APEX研究达到了主要终点（ACR20a），即与安慰剂相比，在成人活动性银屑病关节炎（PsA）患者中减少了体征和症状，同时也达到了其主要次要终点，即在24周时通过放射学进展评估减少了结构损伤的进展。TREMFYA®是首个也是唯一一个获准用于治疗PsA的全人源双效单克隆抗体，它可阻断IL-23，同时与CD64结合，CD64是产生IL-23的细胞上的受体。IL-23是由活化的单核细胞/巨噬细胞以及树突状细胞分泌的细胞因子，已知其为包括活动性银屑病关节炎在内的免疫介导疾病的驱动因素。在3b期APEX研究中，与接受安慰剂的患者相比，接受TREMFYA®治疗的患者在第24周时通过银屑病关节炎改良版van der Heijde-Sharp（vdH-S）评分（包括关节间隙变窄和侵蚀亚评分）评估的结构损伤进展也显著减少。数据与TREMFYA®已知的安全性特征一致，未发现新的安全性信号。“银屑病关节炎可能是一种渐进性和使人衰弱的疾病，如果不进行早期识别和治疗，患者可能会出现不可逆的关节损伤，严重影响其日常活动，”强生公司创新药物部门风湿病学疾病领域负责人Terence Rooney副总裁表示。“这些新的初步数据强调了尽早从源头上解决炎症和结构损伤的重要性。作为唯一一种显示出显著抑制结构损伤的IL-23治疗方法，TREMFYA®为医护人员提供了关键数据，使其患者不必在未来关节健康方面妥协。”APEX是一项3b期研究，具有长达三年的长期扩展数据，将进一步评估TREMFYA®对活动性PsA患者结构损伤抑制的持续疗效。APEX研究的结果正在准备中，将在即将召开的医学会议上展示。药事纵横投稿须知：稿费已上调，欢迎投稿

GenFleet Therapeutics, a commercial-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest phase II data of KROCUS study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cetuximab for first-line non-small cell lung cancer (NSCLC) treatment，in a late-breaking abstract at the mini oral presentation of the 2025 European Lung Cancer Conference (ELCC) annual meeting. Spearheaded by GenFleet in collaboration with top-tier European lung cancer experts, the KROCUS study delivered impressive efficacy across all trial participants and particularly exceptional tumor response among brain-metastatic patients. Additionally, the regimen demonstrated better safety/tolerability over fulzerasib monotherapy in second-line and above NSCLC treatment; KROCUS also indicated superior therapeutic potential over current standard-of-care (SOC) including immunotherapy in first-line KRAS-mutant NSCLC treatment. As a pioneering combination of a KRAS G12C inhibitor (fulzerasib) and an anti-EGFR antibody (cetuximab) in first-line lung cancer treatment, this innovative approach holds the potential to establish the next-generation SOC for first-line NSCLC therapy.  The KROCUS study, led by renowned lung cancer expert Dr. Rafael Rosell, is a European multi-center phase Ib/II trial initiated in March 2023. As of Jan. 14 in 2025, a total of 47 patients were enrolled and 45 of them received at least one post-treatment tumor assessment: the objective response rate (ORR) reached 80% and the disease control rate (DCR) reached 100%. The post-treatment evaluation revealed 3 patients achieved complete response; 33 others reached partial response, including one with 100% tumor shrinkage; 57.8% of patients exhibited ≥50% tumor shrinkage. As data cut-off date, the median follow-up time was 12.8 months, and the median progression-free survival was 12.5 months.  34% of enrolled patients had baseline brain metastasis, and the ORR was 71.4% per RECIST 1.1 among brain-metastatic patients who received at least one post-treatment tumor assessment; all non-target lesions of brain-metastatic patients disappeared or remained stable in the course, and brain target lesions of 5 patients exhibited shrinkage.  The data also showcased the combination therapy’s superior therapeutic potential over immunotherapy or chemo-immunotherapy in first-line KRAS-mutant NSCLC treatment: consistent response rates were observed in KROCUS study across subgroups with varied PD-L1 expressions; since STK11 and KEAP1 have been identified as associated with a lower response to immunotherapy and with poor prognosis for first-line NSCLC SOC, it’s noteworthy that similar responses were discovered in KROCUS study between STK11 or KEAP1 wild-type patients and those with STK11 or KEAP1 co-mutations. The combination therapy displayed a highly favorable safety/tolerability profile, with a lower incidence of treatment-related adverse events (TRAEs) than that of fulzerasib monotherapy for second-line and above NSCLC treatment; grade 3 or higher TRAEs occurred at a considerably lower rate than that of fulzerasib monotherapy (no grade 4 or 5 TRAEs in KROCUS study). The mini oral presentation at ELCC was finished by Dr. Margarita Majem from Hospital de laSanta Creu i Sant Pau, Barcelona. Dr. Rafael Rosell Principal Investigator of KROCUS study “I am delighted to participate in this innovative study on first-line NSCLC treatment. The encouraging efficacy data from phase II trial validated investigators’ initial understanding of the study design. The trial findings also underscored the potential of this regimen, designed according to the KRAS-EGFR synergistic mechanism of the RAS pathway, to become a novel SOC for first-line NSCLC treatment. We are pleased that most brain-metastatic patients, without receiving anti-tumor radiotherapy prior to enrollment, were observed with notable tumor response in the trial. Moreover, the impressive safety/tolerability data bolstered our confidence in exploring KRAS-targeted therapies in first-line lung cancer treatment.”  Yu Wang, M.D.,Ph.D. Chief Medical Officer of GenFleet “Two therapies combining KRAS inhibitors with anti-EGFR antibodies have been approved for late-line colorectal cancer treatment. We have integrated the validated mechanism of dual-target synergy with an innovative first-line setting to treat NSCLC, the tumor type with the highest prevalence of G12C mutation. This regimen is well-positioned to mitigate overlapped toxicities while effectively postponing the onset of potential resistance through the mechanistic synergy. This chemo- and immune-free combination represents a potential novel first-line SOC and leaves space for later-line immunotherapy to extend patients’ overall survival. Fulzerasib is the first KRAS G12C inhibitor launched in China and the third globally; we hope the KROCUS study will move fulzerasib forward to front-line treatment, bringing this promising combo therapy to global patients.” First-line (1L) fulzerasib + cetuximab in KRAS G12Cm advanced NSCLC: updated efficacy and safety from KROCUS study Presenter: Dr. Margarita Majem Abstract No. : LBA1 A total of 47 previously untreated advanced KRAS G12C-mutant NSCLC patients were treated with fulzerasib in combination with cetuximab (fulzerasib 600mg BID + cetuximab 500 mg/m2 Q2W) as of Jan 14, 2025. Efficacy: As of data cutoff date, among the 45 patients who received at least one post-treatment tumor assessment, the ORR was 80% and DCR was 100%; 57.8% had ≥ 50% tumor shrinkage. 16 patients (34%) had brain metastasis; among the 14 brain-metastatic patients that received at least one post-treatment tumor assessment, the ORR per RECIST 1.1 was 71.4%. The median duration of response (DoR) was not reached yet, and 24 patients were still on treatment with a median follow-up of 10.1 months. The mPFS was 12.5 months and the mOS was not reached. Safety: As of data cutoff date, the combination therapy presented a favorable safety/tolerability profile. TRAEs occurred in 87.2% of patients and the majority of the TRAEs were graded 1-2; 14.9% of patients experienced at least one grade 3 TRAEs; no grade 4-5 TRAEs. 2 patients had treatment-related serious adverse events (TRSAE) and the TRSAEs were assessed to be merely related with cetuximab; 3 patients experienced TRAEs, unrelated to fulzerasib, leading to dose discontinuation. KROCUS demonstrated a relatively low occurrence of dose discontinuation or reduction among different first-line G12C-mutant NSLCL combo studies. No new safety signals were identified compared with fulzerasib or cetuximab as single agent.  About KROCUS Study  The  multi-center study of fulzerasib in combination with cetuximab started  in scores of clinical research centers worldwide from March 2023 and  sets its objectives to evaluate the safety/tolerance, efficacy and the  pharmacokinetic characteristics of the combination in advanced NSCLC  patients harboring KRAS G12C mutation. Fulzerasib  the first China-developed KRAS G12C inhibitor that has its NDA  submission accepted and granted with Priority Review Designation by  NMPA. Fulzerasib also received Breakthrough Therapy Designations this  year for treating advanced KRAS G12C-mutant NSCLC patients that have  received at least one systemic therapy and CRC patients who have  received at least two systemic therapies. RAS  protein family can be divided into KRAS, HRAS and NRAS categories. KRAS  mutations are detected in nearly 90% of pancreatic cancer, 30-40% of  colon cancer, and 15-20% lung cancer patients. The occurrence of KRAS  G12C mutation subset is more frequently observed than those with ALK,  ROS1, RET and TRK 1/2/3 mutations combined. GFH925 is a novel, orally  active, potent KRAS G12C inhibitor designed to effectively target the  GTP/GDP exchange, an essential step in pathway activation, by modifying  the cysteine residue of KRAS G12C protein covalently and irreversibly.  Preclinical cysteine selectivity studies demonstrated high selectivity  of fulzerasib towards G12C. Subsequently, fulzerasib effectively  inhibits the downstream signal pathway to induce tumor cells’apoptosis  and cell cycle arrest.  About GenFleet Therapeutics GenFleet  Therapeutics, a clinical-stage biotechnology company focusing on  cutting-edge therapies, is dedicated to serving significant global unmet  medical needs in oncology and immunology. Based on the deep  understanding of disease biology and translational medicine, GenFleet’s  proprietary and fully integrated R&D platform highlights multiple  cutting-edge products with novel mechanisms and global IP.  Since  its inception in 2017, GenFleet has built up industry-leading  capabilities and expertise in developing novel drug candidates - both  small molecules and biologics. Its pipeline includes over 10 programs,  many of which have entered multi-regional clinical trials across China  (including Taiwan), the United States, Europe and Australia. To date,  GenFleet has over 5 clinical studies encompassing IND stage to phase II  studies and completed co-development partnerships with numerous publicly  listed companies worldwide.  GenFleet  is expected to progress additional programs into the clinic, as well as  transition from a clinical stage biotech company into a commercial  stage biopharmaceutical company in the next 3-5 years. Contact Us Tel.: 021-68821388 Mail: pr@genfleet.com; bd@genfleet.com Website: www.genfleet.com Add.: 1206 Zhangjiang Road, Building A, Shanghai